Engineered Fibroblast Growth Factor for Enhanced Wound Healing


Technology # 16-06


A technology for Enhanced Wound Healing


Fibroblast Growth Factor (FGF) is a naturally occurring substance in the body that has many roles.  One of them is to help heal wounds, FGF causes the wound to grow new blood vessels and new nerves.  Currently FGF is used commercially to help in the healing of wounds, however, the version of FGF now used for this purpose is quickly degraded by the presence near a wound of thrombin – which is a blood coagulant.

A new type of engineered FGF has been invented that resists the degradation of thrombin, and has higher biological activity in the blood stream, thus leading to its being more effective in wound healing.  The new version of FGF has been shown to have twice the wound healing property of natural FGF. 




This mutant R136E of the present invention can be used primarily for wound healing purposes, because of its higher stability we can develop FGF-I RI 36E coated surgical patches that can be applied on the wounds directly. As this mutant is thermo stable, major advantage will be the product can be stored and supplied at room temperature, Also the shelf life of the product would be drastically increased. Apart from this due to its resistance to thrombin, it can stay active for a long time in blood stream and can show maximal activity for a prolonged duration of time. By developing a proper delivery system, FGF-I R136E can be directed to the site of internal injury and look for the regeneration of the wounded tissue. A formulation consisting of FGF-l R136E and collagen binding protein and pituitary hormone can be very effective to treat Osteoporosis.




* Biologically extremely active

* Thrombin Resistant

* Thermo stable

* Economically viable

* Stable upon pro-longed storage

* Heparin independent mitogenic activity




The present invention has many advantages over the existing product in the market. The molecule FGF-I R136E is extremely stable and shows much higher bioactivity compared to the existing RI 36K. Also this mutant has a higher thermal stability compared to the wild type and the RI 36K mutant. Further the mutant showed a reduced affinity for heparin which makes it more interesting and intriguing in terms of clinical point of view.


The invention is available for licensing. 

For interested parties seeking further information, feel free to contact:


Mark Allen Lanoue

Technology Manager / Tech Ventures

University of Arkansas

(479) 575-7243





Patent Information:
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Provisional United States 62/315,233 3/30/2016    
For Information, Contact:
Mark Lanoue
Technology Manager
University of Arkansas
Suresh Kumar
Rebecca Kerr
Srinivas Jayanthi
David Mcnabb
David Zaharoff
Kartik Balachandran
Bhanuprasanth Koppolu
© 2020. All Rights Reserved. Powered by Inteum